In new approach, R&D units are spun off
In the old model for drug discovery, R&D is needed to provide a regular crop of new drug prospects to replace the therapies coming off patent. But that's not so in the generics world. Some of India's top generics companies are spinning off their R&D operations into separate companies. Ranbaxy Laboratories and Dr. Reddy's say that these spinoffs make more sense.
- read the report from the Financial Times
Related Articles:
Ranbaxy spins off R&D unit. Report
Ranbaxy touts R&D abilities in new discovery pact. Report
Dr. Reddy's make risky biogenerics move. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
